News Image

For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.

By Mill Chart

Last update: Apr 30, 2024

Our stock screening tool has pinpointed BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) as a growth stock that isn't overvalued. NASDAQ:BMRN is excelling in various growth indicators while maintaining a solid financial footing. Furthermore, it remains attractively priced. Let's delve into the specifics below.

Growth Analysis for NASDAQ:BMRN

ChartMill assigns a Growth Rating to each stock, ranging from 0 to 10. This rating is determined by analyzing different growth elements, including EPS and revenue growth, spanning both historical and future figures. In the case of NASDAQ:BMRN, the assigned 7 reflects its growth potential:

  • The Earnings Per Share has grown by an impressive 265.79% over the past year.
  • The Revenue has grown by 13.74% in the past year. This is quite good.
  • BMRN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.16% yearly.
  • BMRN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 49.53% yearly.
  • BMRN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.54% yearly.
  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

Understanding NASDAQ:BMRN's Valuation Score

To assess a stock's valuation, ChartMill utilizes a Valuation Rating on a scale of 0 to 10. This comprehensive assessment considers various valuation aspects, comparing price to earnings and cash flows, while factoring in profitability and growth. NASDAQ:BMRN has achieved a 6 out of 10:

  • 94.88% of the companies in the same industry are more expensive than BMRN, based on the Price/Earnings ratio.
  • Based on the Price/Forward Earnings ratio, BMRN is valued cheaply inside the industry as 95.39% of the companies are valued more expensively.
  • BMRN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BMRN is cheaper than 95.05% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, BMRN is valued cheaply inside the industry as 94.71% of the companies are valued more expensively.
  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • BMRN has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as BMRN's earnings are expected to grow with 61.93% in the coming years.

Health Assessment of NASDAQ:BMRN

ChartMill employs a unique Health Rating system for all stocks. This rating, ranging from 0 to 10, is determined by analyzing various liquidity and solvency ratios. For NASDAQ:BMRN, the assigned 5 for health provides valuable insights:

  • An Altman-Z score of 5.79 indicates that BMRN is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 5.79, BMRN belongs to the best of the industry, outperforming 81.57% of the companies in the same industry.
  • The Debt to FCF ratio of BMRN (6.67) is better than 94.71% of its industry peers.
  • BMRN has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
  • BMRN has a Current Ratio of 2.74. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.

Understanding NASDAQ:BMRN's Profitability

ChartMill assigns a proprietary Profitability Rating to each stock. The score is computed by evaluating various profitability ratios and margins and ranges from 0 to 10. NASDAQ:BMRN was assigned a score of 7 for profitability:

  • BMRN's Return On Assets of 2.99% is amongst the best of the industry. BMRN outperforms 95.39% of its industry peers.
  • Looking at the Return On Equity, with a value of 4.05%, BMRN belongs to the top of the industry, outperforming 95.22% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 2.42%, BMRN belongs to the top of the industry, outperforming 95.05% of the companies in the same industry.
  • BMRN has a better Profit Margin (8.31%) than 95.73% of its industry peers.
  • With an excellent Operating Margin value of 7.17%, BMRN belongs to the best of the industry, outperforming 95.22% of the companies in the same industry.
  • BMRN has a Gross Margin of 79.23%. This is amongst the best in the industry. BMRN outperforms 87.71% of its industry peers.

Every day, new Affordable Growth stocks can be found on ChartMill in our Affordable Growth screener.

For an up to date full fundamental analysis you can check the fundamental report of BMRN

Keep in mind

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.

Back

BIOMARIN PHARMACEUTICAL INC

NASDAQ:BMRN (6/20/2024, 3:03:43 PM)

After market: 84.71 0 (0%)

84.71

+0.56 (+0.67%)

Follow us for more